Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Lisocabtagene Maraleucel · Breyanzi

Cell therapy (CAR-T) · Kills target cells, directed at CD19 · developed by Juno Therapeutics

Approved FDA, Feb 2021

BMY Developer

1 Registered trials

What is Lisocabtagene Maraleucel?

Lisocabtagene maraleucel is a CD19-directed autologous CAR T-cell therapy, a defined composition of CD4-positive and CD8-positive T cells engineered with an anti-CD19 chimeric antigen receptor carrying a 4-1BB costimulatory domain and a CD3 zeta activation domain. Its CAR binds CD19 on B cells, inducing T-cell activation, proliferation, cytokine release and killing of target cells. It is used in B-cell lymphomas and chronic lymphocytic leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Breyanzi, Liso-cel
Drug type: Cell therapy (CAR-T)
Targets: CD19 (antigen)
Mechanism: Kills target cells, directed at CD19
Pathways: T-cell activation and proliferation, CD3 zeta signaling, 4-1BB costimulation
Therapy area: Oncology
Developer: Juno Therapeutics, Inc. (BMY)
FDA status: Approved as Breyanzi (February 5, 2021), BLA125714 · FDA label

✅ FDA-approved uses

Large B-cell lymphoma
Chronic lymphocytic leukemia
Small lymphocytic lymphoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma

From the indications section of the FDA label (version of Feb 20, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07015242	Phase 2	Lymphoma	Recruiting	BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lymphoma

Other drugs acting on CD19

Blinatumomab FDA approved Inebilizumab FDA approved Loncastuximab tesirine FDA approved Budoprutug Phase 1/2 MK-1045 Phase 2/3

More from Juno Therapeutics

Apixaban FDA approved Belatacept FDA approved Deucravacitinib FDA approved Ipilimumab FDA approved Luspatercept FDA approved Mavacamten FDA approved Nab-paclitaxel FDA approved Nivolumab FDA approved Ozanimod FDA approved Relatlimab FDA approved Repotrectinib FDA approved Xanomeline FDA approved

Sources

Updated Oct 8, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Lisocabtagene Maraleucel

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z